Ray-Coquard, I. L., Braicu, E. I., Hasegawa, K., Lee, J., Wu, X., Black, D., Concin, N., Friedman, C. F., Nacerddine, K., O'Cearbhaill, R. E., Pothuri, B. (2026). FRAmework-01: A two-part phase 3 study of sofetabart mipitecan versus chemotherapy or mirvetuximab soravtansine in platinum-resistant ovarian cancer (PROC), and sofetabart mipitecan plus bevacizumab versus platinum-based chemotherapy plus bevacizumab in platinum-sensitive ovarian cancer (PSOC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps5644